192 related articles for article (PubMed ID: 21713004)
21. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.
Bae IG; Federspiel JJ; Miró JM; Woods CW; Park L; Rybak MJ; Rude TH; Bradley S; Bukovski S; de la Maria CG; Kanj SS; Korman TM; Marco F; Murdoch DR; Plesiat P; Rodriguez-Creixems M; Reinbott P; Steed L; Tattevin P; Tripodi MF; Newton KL; Corey GR; Fowler VG;
J Infect Dis; 2009 Nov; 200(9):1355-66. PubMed ID: 19811099
[TBL] [Abstract][Full Text] [Related]
22. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome.
Kim T; Kim ES; Park SY; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Chong YP; Kim YS
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1473-1481. PubMed ID: 28337607
[TBL] [Abstract][Full Text] [Related]
24. Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.
Chong YP; Park KH; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
Antimicrob Agents Chemother; 2015; 59(6):3541-7. PubMed ID: 25845875
[TBL] [Abstract][Full Text] [Related]
25. Detection of heterogeneous vancomycin-intermediate
Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
[TBL] [Abstract][Full Text] [Related]
26. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
[TBL] [Abstract][Full Text] [Related]
27. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
Pitz AM; Yu F; Hermsen ED; Rupp ME; Fey PD; Olsen KM
J Clin Microbiol; 2011 Jan; 49(1):269-74. PubMed ID: 20962147
[TBL] [Abstract][Full Text] [Related]
28. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
[TBL] [Abstract][Full Text] [Related]
29. Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections.
Butterfield JM; Tsuji BT; Brown J; Ashley ED; Hardy D; Brown K; Forrest A; Lodise TP
Antimicrob Agents Chemother; 2011 Dec; 55(12):5433-7. PubMed ID: 21930887
[TBL] [Abstract][Full Text] [Related]
30. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.
Hu J; Ma XX; Tian Y; Pang L; Cui LZ; Shang H
PLoS One; 2013; 8(9):e73300. PubMed ID: 24069184
[TBL] [Abstract][Full Text] [Related]
31. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.
Honda H; Doern CD; Michael-Dunne W; Warren DK
BMC Infect Dis; 2011 Dec; 11():335. PubMed ID: 22142287
[TBL] [Abstract][Full Text] [Related]
32. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis.
Jacob JT; DiazGranados CA
Int J Infect Dis; 2013 Feb; 17(2):e93-e100. PubMed ID: 23089040
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
[TBL] [Abstract][Full Text] [Related]
34. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
Sader HS; Jones RN; Rossi KL; Rybak MJ
J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
[TBL] [Abstract][Full Text] [Related]
35. [Investigation of the VISA and hVISA Presence in Methicillin-Resistant Staphylococcus aureus Isolates by Various Methods].
Uçar Ş; Duman Y; Tanrıverdi ES; Tekerekoğlu MS; Otlu B
Mikrobiyol Bul; 2022 Oct; 56(4):593-605. PubMed ID: 36458707
[TBL] [Abstract][Full Text] [Related]
36. Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.
Richter SS; Diekema DJ; Heilmann KP; Dohrn CL; Crispell EK; Riahi F; McDanel JS; Satola SW; Doern GV
Antimicrob Agents Chemother; 2014; 58(2):740-5. PubMed ID: 24247138
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China.
Wang Y; Hu YJ; Ai XM; Xu HT; Sun TY
Chin Med J (Engl); 2013 Feb; 126(3):505-9. PubMed ID: 23422115
[TBL] [Abstract][Full Text] [Related]
38. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
[TBL] [Abstract][Full Text] [Related]
39. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.
Maor Y; Hagin M; Belausov N; Keller N; Ben-David D; Rahav G
J Infect Dis; 2009 Mar; 199(5):619-24. PubMed ID: 19199552
[TBL] [Abstract][Full Text] [Related]
40. Attenuated total reflection: Fourier transform infrared spectroscopy for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus.
Wongthong S; Tippayawat P; Wongwattanakul M; Poung-Ngern P; Wonglakorn L; Chanawong A; Heraud P; Lulitanond A
World J Microbiol Biotechnol; 2020 Jan; 36(2):22. PubMed ID: 31955251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
